Sapience Therapeutics, Inc.

11:15 AM - 11:30 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Sapience Therapeutics is focused on discovering and developing peptide-based therapeutics to previously ‘undruggable’ targets for major unmet medical needs, particularly high mortality cancers. With platform-based discovery capabilities, we generate novel peptides to disrupt protein:protein interactions with a focus on disruption of oncogenic transcription complexes, signaling pathways and immune-modulatory mechanisms. We have an emerging pipeline of drug candidates targeting important oncogenic proteins, such as C/EBPβ, β-catenin, and cJun, which have opportunities to address solid tumors and hematologic malignancies, including breast cancer, melanoma, GBM, lung cancer and AML.
Company Type:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
ST101 (C/EBPβ antagonist)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5+
Speaker
photo
President and CEO
Sapience Therapeutics